Literature DB >> 2923805

The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years.

H D Preisler1, K Anderson, K Rai, J Cuttner, J Yates, E DuPre, J F Holland.   

Abstract

Remission duration associated with the administration of conventional maintenance chemotherapy to patients with acute myelogenous leukaemia was evaluated. The records of 760 patients who entered remission between 1974 and 1979 were reviewed. The median duration of remission was 1.1 years with 16% of patients remaining in remission at 8 years. The relapse curve was biphasic with a high rate of relapse during the first 2 1/2 years of remission followed by a much lower relapse rate thereafter. Leukaemic relapses were noted through 8 years of remission. A plateau phase indicating freedom from the risk of leukaemic recurrence is not clearly apparent yet but may exist after the eighth year of remission.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2923805     DOI: 10.1111/j.1365-2141.1989.tb04253.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

2.  Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.

Authors:  Min Fei; Qinglei Hang; Sicong Hou; Songbin He; Changgeng Ruan
Journal:  Mol Cell Biochem       Date:  2013-10-30       Impact factor: 3.396

Review 3.  Genetic and epigenetic heterogeneity and the impact on cancer relapse.

Authors:  Ciaran Hassan; Ebrahim Afshinnekoo; Sheng Li; Shixiu Wu; Christopher E Mason
Journal:  Exp Hematol       Date:  2017-07-10       Impact factor: 3.084

Review 4.  Progress in the treatment of acute myeloid leukaemia in adults.

Authors:  Adrian Newland
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.

Authors:  Dushyant Verma; Hagop Kantarjian; Stefan Faderl; Susan O'Brien; Sherry Pierce; Khanh Vu; Emil Freireich; Michael Keating; Jorge Cortes; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2010-05

Review 6.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

7.  Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.

Authors:  A Wahlin; P Hörnsten; M Hedenus; C Malm
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.

Authors:  Ramadevi Nimmanapalli; Elvira Gerbino; William S Dalton; Varsha Gandhi; Melissa Alsina
Journal:  Br J Haematol       Date:  2008-05-22       Impact factor: 6.998

9.  Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.

Authors:  Min Fei; Qinglei Hang; Sicong Hou; Changgeng Ruan
Journal:  Int J Hematol       Date:  2013-09-14       Impact factor: 2.490

10.  Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.

Authors:  Eytan M Stein; Min Yang; Annie Guerin; Wei Gao; Philip Galebach; Cheryl Q Xiang; Subrata Bhattacharyya; Gaetano Bonifacio; George J Joseph
Journal:  Health Qual Life Outcomes       Date:  2018-09-21       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.